Insulet Posts 28% Revenue Growth and Raises 2017 Outlook on Soaring International Sales
Insulet (NASDAQ: PODD) reported solid third-quarter 2017 financial results after the market closed on Thursday.
The drug delivery company, which is a leader in tubeless insulin pump technology with its Omnipod Insulin Management System, delivered revenue growth of 28% -- which exceeded its guidance -- while its loss per share narrowed. The company also raised its revenue guidance for 2017, as it did in both the first and second quarters.
Shares of Insulet have gained 54.2% in 2017 through Thursday, far outpacing the S&P 500's total return of 17.3%.
Source: Fool.com
Insulet Corp. Aktie
179,35 €
1,49 %
Die Insulet Corp. Aktie wird von der Community stark bevorzugt: Mehrere Buy-Einschätzungen, keine Sell-Einschätzungen.
Das Kursziel von 216 € für Insulet Corp. bedeutet eine deutliche Steigerung von über 20% gegenüber dem aktuellen Kurs von 179.35 €.
